Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Buy
63
PTGX Quote, Financials, Valuation and Earnings
Last price:
$95.24
Seasonality move
:
37.92%
Day range:
$91.70 - $95.39
52-week range:
$33.70 - $95.39
Dividend yield:
0%
P/E ratio:
150.56x
P/S ratio:
29.24x
P/B ratio:
9.24x
Volume:
1.3M
Avg. volume:
972.7K
1-year change:
136.13%
Market cap:
$6B
Revenue:
$434.4M
EPS (TTM):
$0.63
Analysts' Opinion
-
Consensus RatingProtagonist Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $92.83, Protagonist Therapeutics, Inc. has an estimated downside of -2.64% from its current price of $95.35.
-
Price Target UpsideAccording to analysts, the highest upside price target is $115.00 representing 20.61% upside increase from its current price of $95.35.
Fair Value
-
According to the consensus of 9 analysts, Protagonist Therapeutics, Inc. has -2.64% downside to fair value with a price target of $92.83 per share.
PTGX vs. S&P 500
-
Over the past 5 trading days, Protagonist Therapeutics, Inc. has overperformed the S&P 500 by 7.03% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Protagonist Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Protagonist Therapeutics, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Protagonist Therapeutics, Inc. reported revenues of $4.7M.
Earnings Growth
-
Protagonist Therapeutics, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Protagonist Therapeutics, Inc. reported earnings per share of -$0.62.
Enterprise value:
5.4B
EV / Invested capital:
--
Price / LTM sales:
29.24x
EV / EBIT:
283.85x
EV / Revenue:
25.79x
PEG ratio (5yr expected):
--
EV / Free cash flow:
84.69x
Price / Operating cash flow:
96.03x
Enterprise value / EBITDA:
262.99x
Gross Profit (TTM):
$207.7M
Return On Assets:
6.54%
Net Income Margin (TTM):
21.94%
Return On Equity:
7.15%
Return On Invested Capital:
7.03%
Operating Margin:
-985.17%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $323.8M | $209.2M | $4.7M | $4.7M | |
| Gross Profit | -$2.7M | $320.6M | $207.7M | $4M | $4.4M | |
| Operating Income | -$153.2M | $149.1M | $19M | -$41.5M | -$46.4M | |
| EBITDA | -$150.5M | $152.3M | $20.5M | -$40.8M | -$46.1M | |
| Diluted EPS | -$2.61 | $2.67 | $0.63 | -$0.54 | -$0.62 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $327.7M | $276.6M | $324.9M | $476.8M | $586.4M | |
| Total Assets | $373.2M | $282.2M | $330M | $603.9M | $701.7M | |
| Current Liabilities | $39.2M | $36.8M | $27.9M | $44.6M | $44.9M | |
| Total Liabilities | $43.5M | $38.6M | $27.9M | $71.9M | $56.3M | |
| Total Equity | $329.7M | $243.6M | $302.1M | $531.9M | $645.4M | |
| Total Debt | $4.2M | $1.8M | -- | $10.9M | $8.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$118.8M | $230.3M | $65.5M | -$27.9M | -$1.9M | |
| Cash From Investing | $26M | -$352M | -$106.9M | -$208.7M | -$58.6M | |
| Cash From Financing | $170.5M | $22.3M | $24.1M | $12.1M | $5.7M | |
| Free Cash Flow | -$119.5M | $229.2M | $63.7M | -$28.6M | -$2M | |
PTGX
Sector
Market Cap
$6B
$28.7M
Price % of 52-Week High
99.96%
52.89%
Dividend Yield
0%
0%
Shareholder Yield
-0.59%
-1.4%
1-Year Price Total Return
136.13%
-19%
Beta (5-Year)
2.192
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$90.11
200-day SMA
Buy
Level
$59.34
Bollinger Bands (100)
Buy
Level
56.74 - 82.44
Chaikin Money Flow
Buy
Level
82.2M
20-day SMA
Buy
Level
$87.86
Relative Strength Index (RSI14)
Buy
Level
71.30
ADX Line
Buy
Level
40.72
Williams %R
Sell
Level
-0.337
50-day SMA
Buy
Level
$80.91
MACD (12, 26)
Buy
Level
3.35
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
183M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (21.6957)
Buy
CA Score
(Annual)
Level (3.8157)
Sell
Beneish M-Score
(Annual)
Level (6.5501)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-11.7648)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Stock Forecast FAQ
In the current month, PTGX has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The PTGX average analyst price target in the past 3 months is $92.83.
-
Where Will Protagonist Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Protagonist Therapeutics, Inc. share price will drop to $92.83 per share over the next 12 months.
-
What Do Analysts Say About Protagonist Therapeutics, Inc.?
Analysts are divided on their view about Protagonist Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Protagonist Therapeutics, Inc. is a Sell and believe this share price will rise from its current level to $65.00.
-
What Is Protagonist Therapeutics, Inc.'s Price Target?
The price target for Protagonist Therapeutics, Inc. over the next 1-year time period is forecast to be $92.83 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is PTGX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Protagonist Therapeutics, Inc. is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PTGX?
You can purchase shares of Protagonist Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Protagonist Therapeutics, Inc. shares.
-
What Is The Protagonist Therapeutics, Inc. Share Price Today?
Protagonist Therapeutics, Inc. was last trading at $95.24 per share. This represents the most recent stock quote for Protagonist Therapeutics, Inc.. Yesterday, Protagonist Therapeutics, Inc. closed at $95.35 per share.
-
How To Buy Protagonist Therapeutics, Inc. Stock Online?
In order to purchase Protagonist Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PTGX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PTGX
Sector
P/E ratio
150.56x
24.19x
PEG ratio
--
-0.01x
P/B ratio
9.24x
1.84x
Price / LTM sales
29.24x
1.61x
Growth Metrics
PTGX
Sector
Revenue growth
0.79%
4.6%
Earnings growth
-14.73%
11.06%
Revenue (5-year growth)
351.71%
6.5%
Earnings forecast
-$0.43
-$0.20
Profitability
PTGX
Sector
Profitability FY 2024
$431.5M
$3.5M
Return on invested capital
7.03%
-31.61%
Return on assets
6.54%
-27.83%
Return on equity
7.15%
-37.15%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
20
Estimated Next Earnings Date
Feb
5
Balance Sheet
PTGX
Sector
Total cash
$576.1M
$26.8M
Short term investments
$321.7M
$26M
Total assets
$746.8M
$79.7M
Long term debt
$8.5M
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 13
Frequency Electronics, Inc. [FEIM] is up 28.76% over the past day.
Buy
57
MOD alert for Dec 13
Modine Manufacturing Co. [MOD] is down 15.32% over the past day.
Sell
42
OKLO alert for Dec 13
Oklo, Inc. [OKLO] is down 14.91% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
